Vtv Therapeutics Inc., a new company formed by combining Transtech Pharma LLC and its affiliate High Point Pharmaceuticals LLC, has filed to raise up to $172.5 million in an IPO intended to help complete the company's formation and fund new trials of its lead programs, including a phase III study of its lead Alzheimer's disease (AD) drug candidate, azeliragon, and phase II trials of its type 2 diabetes drug candidates.